Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma: What Are the Unanswered Questions?

Rajshekhar Chakraborty; Navneet S. Majhail; Faiz Anwer

doi:10.1001/jamaoncol.2019.1598

Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma: What Are the Unanswered Questions?

Rajshekhar Chakraborty
, Navneet S. Majhail
, Faiz Anwer

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	1095-1096
Number of pages	2
Journal	JAMA Oncology
Volume	5
Issue number	8
DOIs	https://doi.org/10.1001/jamaoncol.2019.1598
State	Published - Aug 2019
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1001/jamaoncol.2019.1598

Cite this

@article{c9f7001e312043ccb3d9f97c149048e7,

title = "Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma: What Are the Unanswered Questions?",

author = "Rajshekhar Chakraborty and Majhail, \{Navneet S.\} and Faiz Anwer",

year = "2019",

month = aug,

doi = "10.1001/jamaoncol.2019.1598",

language = "English (US)",

volume = "5",

pages = "1095--1096",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "8",

}

TY - JOUR

T1 - Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma

T2 - What Are the Unanswered Questions?

AU - Chakraborty, Rajshekhar

AU - Majhail, Navneet S.

AU - Anwer, Faiz

PY - 2019/8

Y1 - 2019/8

UR - https://www.scopus.com/pages/publications/85068319727

UR - https://www.scopus.com/pages/publications/85068319727#tab=citedBy

U2 - 10.1001/jamaoncol.2019.1598

DO - 10.1001/jamaoncol.2019.1598

M3 - Comment/debate

AN - SCOPUS:85068319727

SN - 2374-2437

VL - 5

SP - 1095

EP - 1096

JO - JAMA Oncology

JF - JAMA Oncology

IS - 8

ER -

Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma: What Are the Unanswered Questions?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this